Article
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Leukemia - 1 Jul 2018
Paschka Peter, Schlenk Richard F, Weber Daniela, Benner Axel, Bullinger Lars, Heuser Michael, Gaidzik Verena I, Thol Felicitas, Agrawal Mridul, Teleanu Veronica, Lübbert Michael, Fiedler Walter, Radsak Markus, Krauter Jürgen, Horst Heinz-A, Greil Richard, Mayer Karin, Kündgen Andrea, Martens Uwe, Heil Gerhard, Salih Helmut R, Hertenstein Bernd, Schwänen Carsten, Wulf Gerald, Lange Elisabeth, Pfreundschuh Michael, Ringhoffer Mark, Girschikofsky Michael, Heinicke Thomas, Kraemer Doris, Göhring Gudrun, Ganser Arnold, Döhner Konstanze, Döhner Hartmut
Abstract excerpt
In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as single agent for 1-year maintenance in first-line treatment of adult patients with core-binding factor (CBF) acute myeloid leukemia (AML). The primary combined end point in this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.